Inspire Investing LLC Trims Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Inspire Investing LLC decreased its position in Omnicell, Inc. (NASDAQ:OMCL) by 27.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,406 shares of the company’s stock after selling 3,618 shares during the period. Inspire Investing LLC’s holdings in Omnicell were worth $410,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in OMCL. Nisa Investment Advisors LLC grew its position in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares during the period. GAMMA Investing LLC grew its holdings in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the period. EntryPoint Capital LLC increased its position in shares of Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares during the last quarter. CWM LLC raised its holdings in Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after buying an additional 1,236 shares during the period. Finally, Benjamin Edwards Inc. lifted its position in Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after buying an additional 868 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Down 0.8 %

Omnicell stock opened at $41.10 on Friday. The firm has a market capitalization of $1.89 billion, a P/E ratio of -89.35, a P/E/G ratio of 47.11 and a beta of 0.83. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $45.84. The stock’s fifty day simple moving average is $43.22 and its 200-day simple moving average is $34.24.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.37. The company had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. Omnicell’s revenue was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.29 EPS. As a group, equities analysts expect that Omnicell, Inc. will post 0.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday. Wells Fargo & Company lifted their target price on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. JPMorgan Chase & Co. upped their price target on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and lifted their price objective for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. Finally, Bank of America increased their target price on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.